Balchem (NASDAQ:BCPC) Stock Price Expected to Rise, HC Wainwright Analyst Says

Balchem (NASDAQ:BCPC) had its price target upped by HC Wainwright from $185.00 to $190.00 in a report released on Monday morning,Benzinga reports. The firm currently has a buy rating on the basic materials company’s stock. HC Wainwright also issued estimates for Balchem’s Q4 2024 earnings at $1.10 EPS, FY2024 earnings at $4.01 EPS, Q1 2025 earnings at $1.06 EPS, Q2 2025 earnings at $1.09 EPS, Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.19 EPS and FY2025 earnings at $4.47 EPS.

Separately, StockNews.com raised shares of Balchem from a “hold” rating to a “buy” rating in a report on Monday, October 28th.

Balchem Price Performance

Balchem stock opened at $176.63 on Monday. The business has a 50 day simple moving average of $172.07 and a 200 day simple moving average of $163.86. Balchem has a one year low of $116.84 and a one year high of $186.03. The company has a market capitalization of $5.74 billion, a PE ratio of 47.48, a price-to-earnings-growth ratio of 5.28 and a beta of 0.65. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.98 and a quick ratio of 1.90.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Balchem by 3.8% during the 1st quarter. Vanguard Group Inc. now owns 3,935,935 shares of the basic materials company’s stock valued at $609,873,000 after purchasing an additional 144,423 shares in the last quarter. Conestoga Capital Advisors LLC boosted its stake in Balchem by 1.8% in the third quarter. Conestoga Capital Advisors LLC now owns 1,175,569 shares of the basic materials company’s stock worth $206,900,000 after purchasing an additional 20,360 shares in the last quarter. Geneva Capital Management LLC grew its holdings in shares of Balchem by 1.7% during the third quarter. Geneva Capital Management LLC now owns 779,869 shares of the basic materials company’s stock worth $137,257,000 after purchasing an additional 12,750 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Balchem by 0.9% in the second quarter. Dimensional Fund Advisors LP now owns 697,461 shares of the basic materials company’s stock valued at $107,372,000 after buying an additional 5,977 shares in the last quarter. Finally, Congress Asset Management Co. raised its holdings in shares of Balchem by 12.4% in the third quarter. Congress Asset Management Co. now owns 301,440 shares of the basic materials company’s stock valued at $53,053,000 after buying an additional 33,373 shares during the last quarter. Institutional investors own 87.91% of the company’s stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.